Glucagon-like peptide-1 (GLP-1) agonists in the treatment of obesity
Background: Obesity is an increasing problem in the modern world due to increased morbidity and due to its clinical consequences. It is a chronic disease that causes the development of numerous complications, such as cardiovascular diseases, type 2 diabetes or cancer. The problem of the excessive b...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Kazimierz Wielki University
2023-02-01
|
| Series: | Journal of Education, Health and Sport |
| Subjects: | |
| Online Access: | https://apcz.umk.pl/JEHS/article/view/42726 |
| _version_ | 1797895180934709248 |
|---|---|
| author | Magdalena Mazurek Edyta Białowąs Ewelina Dybała Iwona Cuber Artur Aghadi |
| author_facet | Magdalena Mazurek Edyta Białowąs Ewelina Dybała Iwona Cuber Artur Aghadi |
| author_sort | Magdalena Mazurek |
| collection | DOAJ |
| description |
Background: Obesity is an increasing problem in the modern world due to increased morbidity and due to its clinical consequences. It is a chronic disease that causes the development of numerous complications, such as cardiovascular diseases, type 2 diabetes or cancer. The problem of the excessive body weight is global and affects over 2 billion people around the world. Due to the increasing problem of obesity, pharmacotherapy is recommended in patients with BMI ≥30 kg/m2 or BMI ≥27 kg/m2 with accompanying risk factors.
To fight obesity, however, we primarily use lifestyle modification methods, such as a rational and balanced diet based on reduced caloric content and a low-carbohydrate diet. Another aspect is the use of the optimal amount of exercise of moderate intensity. Only the combination of all these methods gives a real chance for long-term weight loss and maintenance.
Scientific research on GLP-1 analogue drugs such as semaglutide and liraglutide brings us a lot of prospects. The mechanism of their action is based on mimicking the natural GLP-1 secreted in the body.
Aim of the study: The following article as an analysis of the current medical knowledge on the effectiveness and safety of obesity treatment with GLP-1 agonists based on available publications.
Methods and materials: Literature review based on PubMed data using the following key words: obesity; semaglutide; Glucagon-like peptide-1 (GLP-1) agonists
State of knowledge: GLP-1 receptor agonists are incretin drugs. This class of drugs has been approved by the FDA for the treatment of type 2 diabetes.
Results: Numerous studies have shown that chronic systemic delivery of GLP-1 agonists led to weight loss and helped to maintain a lower body weight. Reduction in food intake is reported as the main mechanism.
|
| first_indexed | 2024-04-10T07:21:21Z |
| format | Article |
| id | doaj.art-f84fb8cccf99458881aafb0f96013bf0 |
| institution | Directory Open Access Journal |
| issn | 2391-8306 |
| language | English |
| last_indexed | 2024-04-10T07:21:21Z |
| publishDate | 2023-02-01 |
| publisher | Kazimierz Wielki University |
| record_format | Article |
| series | Journal of Education, Health and Sport |
| spelling | doaj.art-f84fb8cccf99458881aafb0f96013bf02023-02-24T11:43:29ZengKazimierz Wielki UniversityJournal of Education, Health and Sport2391-83062023-02-0113410.12775/JEHS.2023.13.04.022Glucagon-like peptide-1 (GLP-1) agonists in the treatment of obesityMagdalena Mazurek0Edyta Białowąs1Ewelina Dybała2Iwona Cuber3Artur Aghadi4Wojewódzki Szpital Specjalistyczny w LublinieNiepubliczny Zakład Opieki Zdrowotnej ESS-Med ,ul. Tyszkiewiczów 5, 36-100 KolbuszowaWojewódzki Szpital Specjalistyczny w Lublinie Wojewódzki Szpital Specjalistyczny w Lublinie Wojewódzki Szpital Specjalistyczny w Lublinie Background: Obesity is an increasing problem in the modern world due to increased morbidity and due to its clinical consequences. It is a chronic disease that causes the development of numerous complications, such as cardiovascular diseases, type 2 diabetes or cancer. The problem of the excessive body weight is global and affects over 2 billion people around the world. Due to the increasing problem of obesity, pharmacotherapy is recommended in patients with BMI ≥30 kg/m2 or BMI ≥27 kg/m2 with accompanying risk factors. To fight obesity, however, we primarily use lifestyle modification methods, such as a rational and balanced diet based on reduced caloric content and a low-carbohydrate diet. Another aspect is the use of the optimal amount of exercise of moderate intensity. Only the combination of all these methods gives a real chance for long-term weight loss and maintenance. Scientific research on GLP-1 analogue drugs such as semaglutide and liraglutide brings us a lot of prospects. The mechanism of their action is based on mimicking the natural GLP-1 secreted in the body. Aim of the study: The following article as an analysis of the current medical knowledge on the effectiveness and safety of obesity treatment with GLP-1 agonists based on available publications. Methods and materials: Literature review based on PubMed data using the following key words: obesity; semaglutide; Glucagon-like peptide-1 (GLP-1) agonists State of knowledge: GLP-1 receptor agonists are incretin drugs. This class of drugs has been approved by the FDA for the treatment of type 2 diabetes. Results: Numerous studies have shown that chronic systemic delivery of GLP-1 agonists led to weight loss and helped to maintain a lower body weight. Reduction in food intake is reported as the main mechanism. https://apcz.umk.pl/JEHS/article/view/42726obesityagoniści glukagonopodobnego peptydu-1 (GLP-1);semaglutyd |
| spellingShingle | Magdalena Mazurek Edyta Białowąs Ewelina Dybała Iwona Cuber Artur Aghadi Glucagon-like peptide-1 (GLP-1) agonists in the treatment of obesity Journal of Education, Health and Sport obesity agoniści glukagonopodobnego peptydu-1 (GLP-1); semaglutyd |
| title | Glucagon-like peptide-1 (GLP-1) agonists in the treatment of obesity |
| title_full | Glucagon-like peptide-1 (GLP-1) agonists in the treatment of obesity |
| title_fullStr | Glucagon-like peptide-1 (GLP-1) agonists in the treatment of obesity |
| title_full_unstemmed | Glucagon-like peptide-1 (GLP-1) agonists in the treatment of obesity |
| title_short | Glucagon-like peptide-1 (GLP-1) agonists in the treatment of obesity |
| title_sort | glucagon like peptide 1 glp 1 agonists in the treatment of obesity |
| topic | obesity agoniści glukagonopodobnego peptydu-1 (GLP-1); semaglutyd |
| url | https://apcz.umk.pl/JEHS/article/view/42726 |
| work_keys_str_mv | AT magdalenamazurek glucagonlikepeptide1glp1agonistsinthetreatmentofobesity AT edytabiałowas glucagonlikepeptide1glp1agonistsinthetreatmentofobesity AT ewelinadybała glucagonlikepeptide1glp1agonistsinthetreatmentofobesity AT iwonacuber glucagonlikepeptide1glp1agonistsinthetreatmentofobesity AT arturaghadi glucagonlikepeptide1glp1agonistsinthetreatmentofobesity |